首页|我国药物警戒制度发展历程和思考

我国药物警戒制度发展历程和思考

Course of development of pharmocovigilance systems in China

扫码查看
目的 分析药物警戒制度建立的背景及原因,总结药物警戒的实践与思考,为新制度的发展提供借鉴和参考.方法 以法治建设为线索,系统梳理药品不良反应报告制度的起源与发展、面临的问题与新形式,总结近 5年药物警戒制度实践情况,从警戒理念、警戒范围、体系建设方面提出对新制度的思考.结果 药物警戒制度是药品不良反应报告制度发展的必然产物,也是国际药物警戒环境影响的必然趋势.新制度实施 5年间,法律体系、组织体系、技术体系逐步建立与完善,科学研究稳步推进,药物警戒的理念初步形成,同时也面临新制度需要解决的问题.结论 我国药物警戒制度不能一蹴而就,应本着深入研究、统筹考虑、分步实施、分工协作的战略方针逐步推进,以改革、创新为抓手,稳步发展,不断提升.
Objective To analyze the background and reasons for the establishment of the pharmacovigilance system(PVS)in China,summarize the experience related to the PVS,and provide reference for the development of a new system.Methods Starting with the construction of the legal system,the origin and development of the Adverse Drug Reaction Reporting System(ADRRS)were traced,problems with and new challenges to this system were identified,ways in which the PVS was implemented in the past five years were studied,and tips were given about the implementation of the new system in terms of ideas and range of pharmacovigilance,and system construction.Results The PVS was a natural by-product of the ADRRS,and developed out of the international environment for pharmacovigilance.In the first five years since the implementation of the PVS,the legal system,organizational system,and technical system came to be established and improved,research made steady progress,and the notions of pharmacovigilance took shape.At the same time,new problems emerged.Conclusion The PVS in China is unlikely be an instant success.Strategies involving in-depth research,consideration of all the factors as a whole,step-by-step implementation,and division of labor and cooperation are required.Reform and innovation should be given top priority to promote steady development and constant improvement.

pharmacovigilanceadverse drug reactionsadverse drug reaction monitoringdrug supervisionlegal system

王丹、董铎、田春华

展开 >

国家药品监督管理局药品评价中心,国家药品监督管理局药物警戒研究与评价重点实验室,北京 100076

药物警戒 药品不良反应 药品不良反应监测 药品监管 法律体系

国家自然科学基金资助项目

72274065

2024

中国药物警戒
国家药品监督管理局药品评价中心(国家药品不良反应监测中心)

中国药物警戒

CSTPCD
影响因子:1.105
ISSN:1672-8629
年,卷(期):2024.21(7)